Up to 80% of people with hereditary cancer risk remain unidentified, a critical missed cancer prevention opportunity.
At the
#SGOAM26 Plenary, Roni Nitecki Wilke, MD (
@NiteckiRoni @UTMDAnderson) presents data comparing facilitated cascade testing vs. standard care in families with BRCA1/2 mutations to help close this gap.
Key takeaways:
• Facilitated cascade testing significantly increases completion rates vs. standard approaches, with no impact on quality of life.
• Supports a new standard of care, with need for scalable models.